Victoria’s Secret and the Unraveling of an American icon, authors Lauren Sherman and Chantal Fernandez weave together the ...
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...
Traders around the word awaited U.S. inflation data for September—and the implications it will have for rate cuts at the ...
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...
Pharmaceutical giant GSK will pay up to £1.7billion to settle thousands of legal cases that claimed its heartburn drug Zantac ...
The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that ...
The Financial Times top stories cover HSBC's targeted cost-cutting strategy focusing on senior bankers, the UK government's ...
The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...
GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...